CHEMOPREVENTION (OR PREVENTION) OF CERVICAL CANCER WITH FOLIC ACID

这是一项继续研究的建议。 由CPRU第一个方案项目赠款资助。这个 叶酸化学预防宫颈癌研究(CCCFAS) 目前已进入患者收益的第二个年头。目的 这项双盲随机对照试验的目的是确定 口服叶酸治疗预防高血压病的疗效观察 高危患者(那些妇女)宫颈癌的发生 有经活检证实的轻度或中度不典型增生或巨噬细胞增多症 非典型性)。主要的研究终点是不典型增生的消退。 经宫颈涂片和阴道镜检查确诊。 由于延误了两个多小时，因此需要继续进行 初诊病人应计年数，因无能力 NCI及其承包商提供叶酸和安慰剂 以及漫长的FDA审批程序。

This is a proposal for the continuation of a study originally funded in the first CPRU Program Project Grant. The Chemoprevention of Cervical Cancer with Folic Acid Study (CCCFAS) is presently in its second year of patient accrual. The purpose of this double-blind randomized-controlled trial is to determine the effectiveness of oral folic acid therapy in preventing the development of cervical cancer in high-risk patients (those women with biopsy-proven mild or moderate dysplasia or koliocytotic atypia). The major study endpoint is the regression of dysplasia which is ascertained by PAP smear and colposcopy. A continuation was made necessary because of a delay of over two years in beginning patient accrual, due to the inability of the NCI and its contractor to provide the folic acid and placebo tablets and the lengthy FDA approval process.